Vericelは収益の見積りを打破し,第四四半期の結果と収益の成長について株を引き上げた. Vericel beat earnings estimates and raised shares on strong quarterly results and revenue growth.

ヴェリセルは,0.12ドルで予想を上回る0.10ドル/株の四半期利益と675万ドルの収益を予想より2.93億ドル上回り,前年比16.6%の増加を報告した. Vericel reported better-than-expected quarterly earnings, with $0.10 per share, beating estimates by $0.12, and $67.50 million in revenue, surpassing forecasts by $2.93 million, a 16.6% year-over-year increase. スポーツ医薬品や火傷治療のための細胞療法を販売するバイオ医薬品会社は,特定情報なしに2025年度の全面的指導を再確認した. The biopharmaceutical company, which markets cellular therapies for sports medicine and burn care, reaffirmed its full-year 2025 guidance without specifics. 株式は,高額取引量で3.8.75ドルに上昇した. Shares rose to $38.75 on heavy trading volume.